Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.

New fellowships in pediatric brain cancer research

Fall 2023
By Cyrena Musset

The ChadTough Defeat DIPG Foundation began as two organizations founded by Jason and Tammi Carr and Mark and Jenny Mosier. The Carrs and Mosiers both lost their young sons, Chad and Michael, in 2015 to diffuse intrinsic pontine glioma (DIPG) and have since dedicated their lives to raising money and awareness for the most promising childhood brain cancer research around the world. DIPG is a type of tumor that occurs in the brain and spinal cord and can deprive children of the ability to walk, stand, eat, drink, and talk. While many strides have been made in understanding this complex disease, the overall survival rate is less than 1%.

“Together, we can ensure that children diagnosed in the future will have access to effective and lasting treatments and the long, fulfilling lives they deserve.”

Mark Mosier, ChadTough Defeat DIPG Foundation

 ChadTough Defeat DIPG Foundation knows there are more discoveries out there, so with a recent grant of $528,874, it has awarded fellowships to Pruthvi Gowda, PhD, and Joana Graca Marques, PhD, at Dana-Farber Cancer Institute. Training under trailblazing mentors, Nika Danial, PhD, and Mariella Filbin, MD, PhD, respectively, Gowda and Marques are gaining invaluable experience and advancing cutting-edge research that might not otherwise move forward. Specifically, Gowda is analyzing the metabolomic drivers of DIPG and exploring ways to exploit them for therapeutic benefit. In parallel, Marques aims to study a novel vulnerability in DIPG and test potential agents to target it.

“We are grateful for the research being done every day at Dana-Farber, and for the commitment Drs. Gowda and Marques have to developing these discoveries,” said Mark Mosier, co-founder and director of research for ChadTough Defeat DIPG Foundation. “Together, we can ensure that children diagnosed in the future will have access to effective and lasting treatments and the long, fulfilling lives they deserve.”

, , ,
Copy link
Powered by Social Snap